1-7 of 7
Jennifer Mertz
Close
Save search
Sort by
Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Free
John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 670.
https://doi.org/10.1182/blood-2019-127119
Published: 2019
Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Free
Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 4164.
https://doi.org/10.1182/blood-2019-128211
Published: 2019
Journal Articles

A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF)

Free
Marina Kremyanskaya, MD PhD, Ronald Hoffman, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Jennifer Mertz, PhD, Fiona Garner, PhD, Adrian Senderowicz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5481.
https://doi.org/10.1182/blood-2018-99-119157
Published: 2018
Journal Articles

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Free
Ka Tat Siu, PhD, Janani Ramachandran, MA, Andrew J. Yee, MD, Homare Eda, MD PhD, Loredana Santo, MD, Elizabeth K. O'Donnell, MD, Cristina Panaroni, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur Raje, MD
Journal: Blood
Blood (2016) 128 (22): 3320.
https://doi.org/10.1182/blood.V128.22.3320.3320
Published: 2016
Journal Articles

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Free
Ka Tat Siu, PhD, Homare Eda, MDPhD, Loredana Santo, MD, Janani Ramachandran, MA, Miroslav Koulnis, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2015) 126 (23): 4255.
https://doi.org/10.1182/blood.V126.23.4255.4255
Published: 2015
Journal Articles

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Free
Jeremy S. Abramson, MD, Kristie A. Blum, MD, Ian W. Flinn, MD PhD, Martin Gutierrez, MD, Andre Goy, MD, Michael Maris, MD, Michael Cooper, MD, Michael O'Meara, MS, Darrell Borger, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Supko Jeffrey, PhD, Anas Younes, MD
Journal: Blood
Blood (2015) 126 (23): 1491.
https://doi.org/10.1182/blood.V126.23.1491.1491
Published: 2015
Journal Articles

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Free
Robert Sims, PhD, Emmanuel Normant, PharmD, PhD, Peter Sandy, PhD, Jennifer Mertz, PhD, Barbara Bryant, PhD, Michael O'Meara, MS, Marie Green, PhD, Michael Cooper, MD, Jim Audia, PhD
Journal: Blood
Blood (2012) 120 (21): 1331.
https://doi.org/10.1182/blood.V120.21.1331.1331
Published: 2012